The promotion of plasmacytoma tumor growth by mesenchymal stroma is antagonized by basic fibroblast growth factor induced activin A.
The mesenchymal stroma has been shown to play a crucial role in the development of multiple myeloma, partly by secretion of interleukin (IL)-6, that serves as a growth factor for myeloma cells. However, it is still unclear which other stromal molecules are involved in the pathogenesis of this disease. We chose, as a model system, a mouse plasmacytoma cell line, which does not respond to IL-6. We found that the formation of mouse plasmacytoma tumors, in an in vivo skin transplantation model, is facilitated by co-injection of these tumor cells along with a mesenchymal stromal cell. The tumor promoting effect of the stroma was reproduced in an in vitro model; stromal cells induced the proliferation of plasmacytoma cells under serum-free conditions. This growth promotion could not be mimicked by a series of cytokines including IL-6 and insulin-like growth factor (IGF)-I implying a role for yet unidentified stromal factors. The in vivo formation of plasmacytoma tumors was reduced following administration of activin A, a cytokine member of the transforming growth factor (TGF)beta superfamily. Furthermore, the in vitro growth promoting effect of the stroma was abrogated by basic fibroblast growth factor (bFGF) which induced a higher stromal expression of activin A. Our results thus show that mesenchymal stroma expresses plasmacytoma growth stimulating activities that overcome the low constitutive level of the plasmacytoma inhibitor, activin A. The expression of activin A is upregulated by bFGF rendering the stroma suppressive for plasmacytoma growth. The balance between the expression of these regulators may contribute to mesenchymal stroma activity and influence the progression of multiple myeloma.
Shoham
T
T
Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot, Israel.
Sternberg
D
D
Brosh
N
N
Krupsky
M
M
Barda-Saad
M
M
Zipori
D
D
D028341:Activins; D000818:Animals; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D007265:Inhibins / Q000096:biosynthesis / Q000494:pharmacology*; D008297:Male; D051379:Mice; D010954:Plasmacytoma / Q000188:drug therapy / Q000473:pathology*; D017154:Stromal Cells / Q000502:physiology*
D016222:Fibroblast Growth Factor 2; D028341:Activins; D007265:Inhibins